SURVANTA BERACTANT INTRATRACHEAL SUSPENSION Singapour - anglais - HSA (Health Sciences Authority)

survanta beractant intratracheal suspension

abbvie pte. ltd. - phospholipids - solution, sterile - 25 mg/ml - phospholipids 25 mg/ml

BLES SUSPENSION Canada - anglais - Health Canada

bles suspension

bles biochemicals inc - phospholipid; surfactant-associated proteins sp-b and sp-c - suspension - 27mg; 500mcg - phospholipid 27mg; surfactant-associated proteins sp-b and sp-c 500mcg - pulmonary surfactants

NEOSURF SUSPENSION Canada - anglais - Health Canada

neosurf suspension

cipla ltd - phospholipid; surfactant-associated proteins sp-b and sp-c - suspension - 27mg; 500mcg - phospholipid 27mg; surfactant-associated proteins sp-b and sp-c 500mcg - pulmonary surfactants

BLES (bovine lipid extract surfactant) 27 mgml Suspension for Intratracheal Instillation Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bles (bovine lipid extract surfactant) 27 mgml suspension for intratracheal instillation

averroes pharmaceuticals sdn. bhd. - bovine lipids extract surfactant -

SURVANTA- beractant suspension États-Unis - anglais - NLM (National Library of Medicine)

survanta- beractant suspension

abbvie inc. - beractant (unii: s866o45pig) (beractant phospholipids - unii:lja7v5fcw8) - calfactant 25 mg in 1 ml - survanta is indicated for prevention and treatment (“rescue”) of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. none

SURVANTA INTRATRACHEAL SUSPENSION Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

survanta intratracheal suspension

abbvie sdn bhd - beractant (phospolipids)-lung -

SURVANTA 4ML Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

survanta 4ml

abbvie sdn bhd - beractant (phospolipids)-lung -

Inbrija Union européenne - anglais - EMA (European Medicines Agency)

inbrija

acorda therapeutics ireland limited - levodopa - parkinson disease - anti-parkinson drugs - inbrija is indicated for the intermittent treatment of episodic motor fluctuations (off episodes) in adult patients with parkinson’s disease (pd) treated with a levodopa/dopa-decarboxylase inhibitor.

DAUNOXOME 2 Mg/Ml Concentrate for Soln for Inf Irlande - anglais - HPRA (Health Products Regulatory Authority)

daunoxome 2 mg/ml concentrate for soln for inf

galen limited - daunorubicin citrate - concentrate for soln for inf - 2 mg/ml

DAUNOXOME 2 MG/ML CONCENTRATE FOR SOLUTION FOR INF Irlande - anglais - HPRA (Health Products Regulatory Authority)

daunoxome 2 mg/ml concentrate for solution for inf

galen limited - daunorubicin citrate - concentrate for susp for inf - 2 mg/ml